Completed Clinical Trials

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

By April 24, 2017 No Comments

Condition

Carcinoma, Non-Small-Cell Lung|Mesothelioma

Estimated Enrollment: 18

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CLBH589B2109

Study First Received: September 26, 2007

Last Updated: November 26, 2012

Estimated Primary Completion Date: January 2009

 

Primary Outcome Measures:

Pharmacokinetic (PK) parameters|Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs)|Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation|Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation

Sponsors and Collaborators:

Novartis Pharmaceuticals|Novartis

Website Link: https://ClinicalTrials.gov/show/NCT00535951

Leave a Reply

Call Now